Download PDF
Dtsch Med Wochenschr 2012; 137(45): 2332-2335
DOI: 10.1055/s-0032-1327253
Prinzip & Perspektive | Review article
Nephrologie, Transplantationsmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Renale Ko-Morbidität nach Transplantation solider Organe

Renal co-morbidity after solid organ transplantation
M. Schiffer
1   Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

18 June 2012

20 September 2012

Publication Date:
30 October 2012 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Chronisches Nierenversagen - Herz-Transplantation - Lungen-Transplantation - Leber-Transplantation

Keywords

Chronic kidney disease - heart transplantation - lung transplantation - liver transplantation
 

  • Literatur

  • 1 EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417
    CrossrefPubMedGoogle Scholar
  • 2 Backman L, Reisaeter AV, Wramner L et al. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus. Clin Transplant 2006; 20: 336-339
    CrossrefPubMedGoogle Scholar
  • 3 Barri YM, Sanchez EQ, Jennings LW et al. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl 2009; 15: 475-483
    CrossrefPubMedGoogle Scholar
  • 4 Bjarnadottir M, Grubb A, Olafsson I. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 1995; 55: 617-623
    CrossrefPubMedGoogle Scholar
  • 5 Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18: 3031-3041
    CrossrefPubMedGoogle Scholar
  • 6 Bokenkamp A, van Wijk JA, Lentze MJ et al. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem 2002; 48: 1123-1126
    PubMedGoogle Scholar
  • 7 Boyer O, Le Bidois J, Dechaux M et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005; 79: 1405-1410
    CrossrefPubMedGoogle Scholar
  • 8 Boyle JM, Moualla S, Arrigain S et al. Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation. Am J Kidney Dis 2006; 48: 787-796
    CrossrefPubMedGoogle Scholar
  • 9 Cabezuelo JB, Ramirez P, Rios A et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69: 1073-1080
    CrossrefPubMedGoogle Scholar
  • 10 Castroagudin JF, Molina E, Romero R et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15: 1792-1797
    CrossrefPubMedGoogle Scholar
  • 11 Charlton MR, Wall WJ, Ojo AO et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: 1-34
    CrossrefPubMedGoogle Scholar
  • 12 Cholongitas E, Shusang V, Marelli L et al. Review article: renal function assessment in cirrhosis – difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-978
    CrossrefPubMedGoogle Scholar
  • 13 Clajus C, Hanke N, Gottlieb J et al. Renal comorbidity after solid organ and stem cell transplantation. Am J Transplant 2012; 12: 1691-1699
    CrossrefPubMedGoogle Scholar
  • 14 Creput C, Blandin F, Deroure B et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl 2007; 13: 1004-1010
    CrossrefPubMedGoogle Scholar
  • 15 Davis CL, Feng S, Sung R et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7: 1702-1709
    CrossrefPubMedGoogle Scholar
  • 16 Fan Y, Xiao YB, Weng YG. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transplantation proceedings 2009; 41: 1821-1824
    CrossrefPubMedGoogle Scholar
  • 17 Fioretto P, Kim Y, Mauer M. Diabetic nephropathy as a model of reversibility of established renal lesions. Curr Opin Nephrol Hypertens 1998; 7: 489-494
    CrossrefPubMedGoogle Scholar
  • 18 Fioretto P, Steffes MW, Mihatsch MJ et al. Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 1995; 48: 489-495
    CrossrefPubMedGoogle Scholar
  • 19 Fisher NC, Nightingale PG, Gunson BK et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59-66
    CrossrefPubMedGoogle Scholar
  • 20 Flechner SM. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc 2008; 40: 25-28
    CrossrefPubMedGoogle Scholar
  • 21 Groetzner J, Kaczmarek I, Schulz U et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009; 87: 726-733
    CrossrefPubMedGoogle Scholar
  • 22 Haas M, Kain R, Mayer G et al. Heart transplantation or combined heart/kidney transplantation? Even one renal biopsy may fool you. Nephrol Dial Transplant 1999; 14: 1014-1015
    CrossrefPubMedGoogle Scholar
  • 23 Herlenius G, Fistouris J, Olausson M et al. Early renal function post-liver transplantation is predictive of progressive chronic kidney disease. Scand J Gastroenterol 2008; 43: 344-349
    CrossrefPubMedGoogle Scholar
  • 24 Ishani A, Erturk S, Hertz MI et al. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61: 2228-2234
    CrossrefPubMedGoogle Scholar
  • 25 Karie-Guigues S, Janus N, Saliba F et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009; 15: 1083-1091
    CrossrefPubMedGoogle Scholar
  • 26 Kim JY, Akalin E, Dikman S et al. The variable pathology of kidney disease after liver transplantation. Transplantation 2010; 89: 215-221
    CrossrefPubMedGoogle Scholar
  • 27 Lindelow B, Bergh CH, Herlitz H et al. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11: 951-957
    PubMedGoogle Scholar
  • 28 Mehra MR, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant 2006; 25: 1024-1042
    CrossrefPubMedGoogle Scholar
  • 29 O'Riordan A, Wong V, McCormick PA et al. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21: 2630-2636
    CrossrefPubMedGoogle Scholar
  • 30 Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940
    CrossrefPubMedGoogle Scholar
  • 31 Orlando R, Mussap M, Plebani M et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48: 850-858
    PubMedGoogle Scholar
  • 32 Poge U, Gerhardt T, Stoffel-Wagner B et al. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant 2006; 21: 660-664
    CrossrefPubMedGoogle Scholar
  • 33 Risch L, Herklotz R, Blumberg A et al. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47: 2055-2059
    PubMedGoogle Scholar
  • 34 Rocha PN, Rocha AT, Palmer SM et al. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 2005; 5: 1469-1476
    CrossrefPubMedGoogle Scholar
  • 35 Rothenburger M, Zuckermann A, Bara C et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007; 26: 305-311
    CrossrefPubMedGoogle Scholar
  • 36 Rubel JR, Milford EL, McKay DB et al. Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 2004; 23: 289-300
    CrossrefPubMedGoogle Scholar
  • 37 Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591
    CrossrefPubMedGoogle Scholar
  • 38 Schwarz A, Haller H, Schmitt R et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 2010; 10: 2017-2025
    CrossrefPubMedGoogle Scholar
  • 39 Shemesh O, Golbetz H, Kriss JP et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838
    CrossrefPubMedGoogle Scholar
  • 40 Skluzacek PA, Szewc RG, Nolan CR et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42: 1169-1176
    CrossrefPubMedGoogle Scholar
  • 41 Soccal PM, Gasche Y, Favre H et al. Improvement of drug-induced chronic renal failure in lung transplantation. Transplantation 1999; 68: 164-165
    PubMedGoogle Scholar
  • 42 Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20: 2305-2313
    CrossrefPubMedGoogle Scholar
  • 43 White CA, Akbari A, Doucette S et al. Estimating glomerular filtration rate in kidney transplantation: is the new chronic kidney disease epidemiology collaboration equation any better?. Clinical chemistry 2010; 56: 474-477
    CrossrefPubMedGoogle Scholar
  • 44 Wilkinson A, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver Transpl 2005; S47-51
    PubMedGoogle Scholar